Drug Channels
SEPTEMBER 9, 2021
Cardinal Health recently released the annual report for its 2021 fiscal year, which ended on June 30. See the links below. Today, I delve into the financials behind Cardinal’s relationship with its largest customer, CVS Health. In Cardinal’s 2021 fiscal year, CVS purchased more than $42 billion in pharmaceuticals from the wholesaler—about double the figure from 10 years ago.
Drug Patent Watch
SEPTEMBER 10, 2021
This chart shows the drugs with the most patents in Bulgaria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Bulgaria? appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
SEPTEMBER 10, 2021
POSEIDON Phase III trial showed the addition of a short course of tremelimumab to Imfinzi plus chemotherapy improved patient outcomes without an increase in treatment discontinuation. Positive results from the POSEIDON Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, when added to platinum-based chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) compared to chemothe
Olympian Clinical Research
SEPTEMBER 7, 2021
Obsessive-compulsive disorder (OCD) is a common mental illness that affects people of all ages, races and genders. Individuals affected with this disorder often have trouble recognizing and managing their obsessive, recurring thoughts, which lead them to engage in compulsive and repetitive behaviors. Luckily, people with OCD can live full and complete lives with some simple OCD tips. .
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Channels
SEPTEMBER 8, 2021
Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Friday, September 24, 2021, from 12:00 p.m. to 1:30 p.m. ET This page describes the event and explains how to purchase a registration. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
SEPTEMBER 5, 2021
This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
SEPTEMBER 10, 2021
Today, SVG Ventures | THRIVE and Bayer announced the winners of their 2021 Sustainability Challenge. The Sustainable Startup Award was presented to Haystack , a US based company that enables carbon market scalability by helping farmers and carbon markets quantify carbon accurately and cost-effectively. Haystack will receive a prize package that includes investment from SVG Ventures and a place in THRIVE’s award winning Accelerator Program, in addition to access to Bayer’s investment and
The Pharma Data
SEPTEMBER 10, 2021
–Final results from PROviDE, a long-term, real-world study, evaluating the effectiveness of DUODOPA® (levodopa-carbidopa intestinal gel) in patients with advanced Parkinson’s disease –Additional poster presentations planned on the real-world efficacy and safety of BOTOX® (onabotulinumtoxinA) for the treatment of spasticity and cervical dystonia –Research highlights AbbVie’s continued focus on advancing the management of movement disorders.
Drug Patent Watch
SEPTEMBER 10, 2021
Annual Drug Patent Expirations for TRIGLIDE Triglide is a drug marketed by Skyepharma Ag and is included in one NDA. There is one patent protecting this drug. This drug has…. The post New patent expiration for Skyepharma Ag drug TRIGLIDE appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
SEPTEMBER 9, 2021
Annual Drug Patent Expirations for JARDIANCE Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from four suppliers. There are six patents…. The post New patent for Boehringer Ingelheim drug JARDIANCE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 9, 2021
Annual Drug Patent Expirations for COTELLIC Cotellic is a drug marketed by Genentech Inc and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for Genentech Inc drug COTELLIC appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
SEPTEMBER 8, 2021
Roche to acquire the TIB Molbiol Group with the expectation to close in fourth quarter of 2021. TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche`s LightCycler PCR instruments.
The Pharma Data
SEPTEMBER 8, 2021
Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. (NASDAQ: KDMN) a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical needs.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
The Pharma Data
SEPTEMBER 8, 2021
–Results from an open-label, multicenter extension to the pivotal Phase 3 ADVANCE trial evaluate the safety and tolerability of oral atogepant for the preventive treatment of migraine –Data from the observational cross-sectional UNIVERSE study highlight the real-world effectiveness and patient satisfaction of ubrogepant in acute migraine. –Results from a post-hoc analysis of the Phase 3 PREEMPT trials evaluate the use of BOTOX® (onabotulinumtoxinA) for chronic migraine –T
The Pharma Data
SEPTEMBER 8, 2021
The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints. Rilzabrutinib’s safety profile remained consistent with previous results and no new safety signals were identified. The Phase 3 study, which is the first placebo-controlled trial of a BTK inhibitor in pemphigus, enrolled adult patients with moderate-to-severe pemphigus vulgaris or pemphigus foliaceus.
The Pharma Data
SEPTEMBER 8, 2021
Long-term data show durable survival benefits with Opdivo (nivolumab) plus Yervoy, (ipilimumab), including five-year results in renal cell carcinoma and three-year results in malignant pleural mesothelioma. Phase 3 data from RELATIVITY-047 demonstrate prolonged benefit beyond initial treatment of the LAG-3 blocking antibody relatlimab and PD-1 inhibitor nivolumab fixed-dose combination for patients with previously untreated unresectable or metastatic melanoma.
The Pharma Data
SEPTEMBER 9, 2021
Riders aspire to raise more than $1 million for the V Foundation for Cancer Research and make a profound difference for patients and families touched by cancer. Today, Bristol Myers Squibb (NYSE:BMY) employee Mark DeLong is joining more than 230 of his colleagues in Coast 2 Coast 4 Cancer , an epic ~3,000-mile cycling event on two unique routes (~6,000 miles total) to raise funds for the V Foundation for Cancer Research.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Pharma Data
SEPTEMBER 9, 2021
Bristol Myers Squibb will announce results for the third quarter of 2021 on Wednesday, October 27, 2021. During a conference call at 8 a.m. ET on October 27, 2021, company executives will review financial results and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at [link] or by using this link which becomes active 15 minutes prior to the scheduled start time and entering your information to be connected.
The Pharma Data
SEPTEMBER 9, 2021
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a network meta-analysis examining the efficacy of AJOVY (fremanezumab-vfrm), atogepant and Nurtec ® ODT (rimegepant) in the preventive treatment of episodic migraine (EM). This data will be presented as a late-breaker ePoster during the International Headache Society (IHS) and European Headache Federation (EHF) Joint Congress taking place virtually on Sept.
The Pharma Data
SEPTEMBER 9, 2021
PT027 significantly reduced the risk of severe exacerbations compared to albuterol in patients with moderate to severe asthma in MANDALA trial when used as a rescue medicine in response to symptoms. PT027 significantly improved lung function compared to individual components in mild to moderate asthma in DENALI trial . Positive high-level results from the MANDALA and DENALI Phase III trials of PT027 (albuterol/budesonide), at both 180/160mcg and 180/80mcg doses, met all primary endpoints demons
Drug Patent Watch
SEPTEMBER 8, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for DESCOVY Descovy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are six…. The post New patent expiration for Gilead Sciences drug DESCOVY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for COMPLERA Complera is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are twelve…. The post New patent expiration for Gilead Sciences drug COMPLERA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for ATRIPLA Atripla is a drug marketed by Gilead Sciences and is included in one NDA. It is available from two suppliers. There are nine patents…. The post New patent expiration for Gilead Sciences drug ATRIPLA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for EMTRIVA Emtriva is a drug marketed by Gilead and is included in two NDAs. It is available from two suppliers. There are two patents protecting…. The post New patent expiration for Gilead drug EMTRIVA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for GENVOYA Genvoya is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are thirteen…. The post New patent expiration for Gilead Sciences drug GENVOYA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for ODEFSEY Odefsey is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are ten…. The post New patent expiration for Gilead Sciences drug ODEFSEY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for TRUVADA Truvada is a drug marketed by Gilead and is included in one NDA. It is available from seven suppliers. There are six patents protecting…. The post New patent expiration for Gilead drug TRUVADA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for STRIBILD Stribild is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent expiration for Gilead Sciences drug STRIBILD appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for PERSERIS+KIT Perseris Kit is a drug marketed by Indivior Inc and is included in one NDA. It is available from one supplier. There are eight…. The post New patent for Indivior Inc drug PERSERIS KIT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for ORLADEYO Orladeyo is a drug marketed by Biocryst and is included in one NDA. There are four patents protecting this drug. This drug has thirty-six…. The post New patent for Biocryst drug ORLADEYO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 8, 2021
Annual Drug Patent Expirations for SLYND Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. It is available from one supplier. There are five…. The post New patent for Exeltis Usa drug SLYND appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
85 
Let's personalize your content